MYGNMyriad Genetics, Inc.
3.860USD+1.05%Mkt Cap: 364.10M USDP/E: Last update: 2026-05-26

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides …

Indicators:|

Key Statistics

Company
Market Cap364.10M USD
Enterprise Value218.59M USD
Revenue (TTM)557.00M USD
Gross Profit576.60M USD
Net Income (TTM)-365.90M USD
Revenue/Share7.452 USD
Last Price3.860 USD
Fiscal Year EndDec 2025
MR QuarterDec 2020
Employees2.7K
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISINUS62855J1043
Valuation
P/E (Trailing)
P/E (Forward)24.44
PEG1.24
EV/EBITDA-1.95
EV/Revenue0.39
P/S0.66
P/B1.09
EPS (TTM)-4.31
EPS (Forward)0.16
52W Range
3.5307% of range8.590
52W High8.590 USD
52W Low3.530 USD
Profitability
Gross Margin69.93%
Oper. Margin-21.41%
EBITDA Margin-20.09%
Profit Margin-44.38%
ROE-99.43%
ROA-51.78%
Growth
Revenue Growth-20.80%
Earnings Growth
Cash Flow & Leverage
Operating CF1.80M USD
CapEx (TTM)27.40M USD
FCF Margin-8.27%
FCF Yield-12.65%
Net Debt-150.70M USD
Net Debt/EBITDA1.35
Balance Sheet
Debt/Equity0.57
Current Ratio2.67
Quick Ratio1.65
Book Value/Sh3.574 USD
Cash/Share1.596 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Splits
Last Split2:1
Split DateMar 26, 2009
Analyst Consensus
Rating3.0 (Hold)
Target (Mean)6.250 USD
Target Range4.000 USD10.00 USD
# Analysts8
Ownership
Shares Out.94.45M
Float85.99M
Insiders3.26%
Institutions97.69%
Short Interest
Short Ratio7.7d
Short % Float8.56%
Short % Out.8.35%
Shares Short7.88M
Short (prev mo.)8.76M
Technical
SMA 504.538 (-14.9%)
SMA 2006.022 (-35.9%)
Beta1.64
S&P 52W Chg28.31%
Avg Vol (30d)1.54M
Avg Vol (10d)1.73M
Technical Indicators
RSI (14)
MACD
MACD Signal
MACD Hist.
BB Upper
BB Middle
BB Lower
BB Width
ATR (14)
Vol Ratio (20d)